AUPH Aurinia Pharmaceuticals Inc.
FY2025 10-K
Aurinia Pharmaceuticals Inc. (AUPH) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of LUPKYNIS, an immunosuppressant drug, plus pipeline advancement of aritinercept
- • Emphasis on aritinercept clinical development with noted risks of delays, effectiveness, and regulatory approval uncertainty
Management Discussion & Analysis
- • Revenue $283.1M, up 20% YoY; Net product sales $271.3M up 25%, License revenue $11.7M down 38%
- • Gross margin stable at 88%; Operating expenses $178.1M down 26% from $239.8M; Operating income $104.9M vs loss $4.7M
Risk Factors
- • Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS
- • Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets
Financial SummaryXBRL
Revenue
$283M
Net Income
$287M
Operating Margin
37.1%
Net Margin
101.5%
ROE
49.4%
Total Assets
$752M
EPS (Diluted)
$2.07
Operating Cash Flow
$136M
Source: XBRL data from Aurinia Pharmaceuticals Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Aurinia Pharmaceuticals Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.